Bioforce Nanosciences Holdings Stock Debt To Equity
| BFNH Stock | USD 0.75 0.08 11.94% |
BioForce Nanosciences Holdings fundamentals help investors to digest information that contributes to BioForce Nanosciences' financial success or failures. It also enables traders to predict the movement of BioForce Pink Sheet. The fundamental analysis module provides a way to measure BioForce Nanosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioForce Nanosciences pink sheet.
BioForce |
BioForce Nanosciences Holdings Company Debt To Equity Analysis
BioForce Nanosciences' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current BioForce Nanosciences Debt To Equity | 4.61 % |
Most of BioForce Nanosciences' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioForce Nanosciences Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
According to the company disclosure, BioForce Nanosciences Holdings has a Debt To Equity of 4.61%. This is 94.18% lower than that of the Consumer Defensive sector and 95.8% lower than that of the Packaged Foods industry. The debt to equity for all United States stocks is 90.53% higher than that of the company.
BioForce Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioForce Nanosciences' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of BioForce Nanosciences could also be used in its relative valuation, which is a method of valuing BioForce Nanosciences by comparing valuation metrics of similar companies.BioForce Nanosciences is currently under evaluation in debt to equity category among its peers.
BioForce Fundamentals
| Return On Asset | -21.84 | |||
| Current Valuation | 50.2 M | |||
| Shares Outstanding | 29.27 M | |||
| Shares Owned By Insiders | 82.29 % | |||
| Price To Earning | (1.52) X | |||
| Price To Book | 866.24 X | |||
| Price To Sales | 3,841 X | |||
| Gross Profit | 4.36 K | |||
| EBITDA | (501.95 K) | |||
| Net Income | (501.95 K) | |||
| Cash And Equivalents | 9.23 K | |||
| Total Debt | 156.87 K | |||
| Debt To Equity | 4.61 % | |||
| Current Ratio | 0.01 X | |||
| Book Value Per Share | (0.04) X | |||
| Cash Flow From Operations | (77.77 K) | |||
| Earnings Per Share | (0.02) X | |||
| Target Price | 0.25 | |||
| Beta | -1.93 | |||
| Market Capitalization | 72.74 M | |||
| Total Asset | 11.14 K | |||
| Retained Earnings | (21 K) | |||
| Working Capital | 14 K | |||
| Current Asset | 15 K | |||
| Current Liabilities | 1 K | |||
| Net Asset | 11.14 K |
About BioForce Nanosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioForce Nanosciences Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioForce Nanosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioForce Nanosciences Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in BioForce Pink Sheet
BioForce Nanosciences financial ratios help investors to determine whether BioForce Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioForce with respect to the benefits of owning BioForce Nanosciences security.